• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ACS 患者中 CHADS-VASc 和 GRACE 风险评分的预后价值。

The prognostic value of CHADS-VASc and GRACE risk scores in patients with ACS.

机构信息

1(st) Department of Cardiology, University of Athens, Greece.

1(st) Department of Cardiology, University of Athens, Greece.

出版信息

Hellenic J Cardiol. 2019 Sep-Oct;60(5):305-308. doi: 10.1016/j.hjc.2018.03.001. Epub 2018 Mar 27.

DOI:10.1016/j.hjc.2018.03.001
PMID:29601955
Abstract

OBJECTIVE

Cardiovascular diseases are the first cause of death in western societies. Therapeutic interventions in the individual patient should be guided by the so-called ischemic risk of this patient.

PURPOSE

The aim of the study was to study the ischemic prognostic scores GRACE and CHADS-VASc, in patients underwent angioplasty to highlight which best predicts better the ischemic risk.

METHODS

Consecutives patients who underwent Percutaneous Coronary Intervention (PCI) due to Acute Coronary Disease, or elective PCI in one centre in Athens, Greece, where included in the study. The GRACE score and the CHADS-VASc score were calculated.

RESULTS

667 patients participated in the study with an average age of 61 ± 11 years and were followed-up for 2 years. The GRACE score and its predicted incidence at 3 years, was compared to the CHADS-VASc score. CHADS-VASc score was able to show a marginally better prognosis of future ischemic events, with an AUC of 0.624 vs 0.608 of the GRACE score.

CONCLUSIONS

In our study, The CHADS-VASc score managed to predict, marginally better, the appearance of MACCE over GRACE, in patients with angioplasty.

摘要

目的

心血管疾病是西方社会的首要死因。对个体患者的治疗干预应根据该患者的所谓缺血风险来指导。

目的

本研究旨在研究行血管成形术的患者的缺血预后评分 GRACE 和 CHADS-VASc,以突出哪种评分能更好地预测缺血风险。

方法

连续入组因急性冠脉疾病行经皮冠状动脉介入治疗(PCI)或在希腊雅典一家中心行择期 PCI 的患者,将其纳入研究。计算 GRACE 评分和 CHADS-VASc 评分。

结果

667 例患者参与了这项研究,平均年龄为 61±11 岁,随访 2 年。比较了 GRACE 评分及其预测的 3 年缺血事件发生率与 CHADS-VASc 评分。CHADS-VASc 评分在预测未来缺血事件方面显示出略好的预后,AUC 为 0.624 对 GRACE 的 0.608。

结论

在我们的研究中,CHADS-VASc 评分在预测血管成形术后 MACCE 的出现方面,略优于 GRACE。

相似文献

1
The prognostic value of CHADS-VASc and GRACE risk scores in patients with ACS.ACS 患者中 CHADS-VASc 和 GRACE 风险评分的预后价值。
Hellenic J Cardiol. 2019 Sep-Oct;60(5):305-308. doi: 10.1016/j.hjc.2018.03.001. Epub 2018 Mar 27.
2
Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.CHADS2和CHA2DS2-VASc评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者出院后结局的预后价值。
Medicine (Baltimore). 2020 Jul 24;99(30):e21321. doi: 10.1097/MD.0000000000021321.
3
Usefulness of the CHADS-VASc Score to Predict Adverse Outcomes in Acute Coronary Syndrome Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.CHADS-VASc 评分在经皮冠状动脉介入治疗的无房颤急性冠状动脉综合征患者中预测不良结局的价值。
Am J Cardiol. 2019 Aug 15;124(4):476-484. doi: 10.1016/j.amjcard.2019.05.036. Epub 2019 May 29.
4
CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events.非ST段抬高型急性冠状动脉综合征患者的CHA2DS2-VASc-HS评分:评估冠状动脉疾病的严重程度和复杂性,并与其他评分系统比较以预测院内主要不良心血管事件
Anatol J Cardiol. 2016 Oct;16(10):742-748. doi: 10.14744/AnatolJCardiol.2015.6593. Epub 2016 Mar 23.
5
Coronary artery disease severity and risk stratification of patients with non ST-elevation acute coronary syndrome using CHADS-VASc-HSF score.采用 CHADS-VASc-HSF 评分评估非 ST 段抬高型急性冠脉综合征患者的冠状动脉疾病严重程度和风险分层。
BMC Cardiovasc Disord. 2024 May 21;24(1):263. doi: 10.1186/s12872-024-03929-5.
6
Value of Adding the CHA2DS2-VASc Score to the GRACE Score for Mortality Risk Prediction in Patients With Acute Coronary Syndrome.CHA2DS2-VASc 评分对 GRACE 评分在急性冠状动脉综合征患者死亡风险预测中的价值。
Am J Cardiol. 2019 Jun 1;123(11):1751-1756. doi: 10.1016/j.amjcard.2019.02.045. Epub 2019 Mar 9.
7
Relationship between CHADS-VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome.急性冠状动脉综合征患者 CHADS-VASc 评分、冠状动脉疾病严重程度、残余血小板反应性与长期临床结局的关系。
Int J Cardiol. 2018 Jul 1;262:9-13. doi: 10.1016/j.ijcard.2018.03.086. Epub 2018 Mar 20.
8
Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome.急性冠状动脉综合征经皮冠状动脉介入治疗后CHA2DS2-VASC评分对造影剂肾病的预测价值
Am J Cardiol. 2017 Mar 15;119(6):819-825. doi: 10.1016/j.amjcard.2016.11.033. Epub 2016 Dec 18.
9
CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome.CHA2DS2-VASc评分作为急性冠状动脉综合征经皮冠状动脉介入治疗后对比剂肾病的新型预测指标。
Indian Heart J. 2019 Jul-Aug;71(4):303-308. doi: 10.1016/j.ihj.2019.09.005. Epub 2019 Sep 9.
10
The Predictive Value of CHADS-VASc Score on In-Hospital Death and Adverse Periprocedural Events Among Patients With the Acute Coronary Syndrome and Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: A 10-Year National Inpatient Sample (NIS) Analysis.CHADS-VASc评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征合并心房颤动患者住院死亡及围手术期不良事件的预测价值:一项为期10年的全国住院患者样本(NIS)分析
Cardiovasc Revasc Med. 2021 Aug;29:61-68. doi: 10.1016/j.carrev.2020.08.003. Epub 2020 Aug 7.

引用本文的文献

1
Evaluation of R2CHADS2, R2CHA2DS2-VASc, and R2CHA2DS2-VA Scores for the Prediction of In-Hospital Mortality in Patients with ST-Elevation Myocardial Infarction.评估R2CHADS2、R2CHA2DS2-VASc和R2CHA2DS2-VA评分对ST段抬高型心肌梗死患者院内死亡率的预测价值。
J Clin Med. 2025 Jun 30;14(13):4624. doi: 10.3390/jcm14134624.
2
New R-CHADS-VASc score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.新的R-CHADS-VASc评分可预测ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗后的无复流现象及长期预后。
Front Cardiovasc Med. 2022 Oct 13;9:899739. doi: 10.3389/fcvm.2022.899739. eCollection 2022.
3
Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention.
GRACE和CHA2DS2-VASc评分在接受经皮冠状动脉介入治疗的房颤患者中的预后价值。
Ann Med. 2021 Dec;53(1):2215-2224. doi: 10.1080/07853890.2021.2004321.
4
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.新型 CHADS-VASc-HSF 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象。
BMC Cardiovasc Disord. 2020 Jul 25;20(1):346. doi: 10.1186/s12872-020-01623-w.